MedTrace Logo

Impact of the Microbiota on the Likelihood of Renal Graft Rejection

NCT04736381 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-04-10

No results posted yet for this study

Summary

Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.

Conditions

  • Kidney Transplant Rejection

Interventions

DRUG

Belatacept Injection [Nulojix]

Drugs administrated are part of the usual care

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Antoine Durrbach, MD-PhD · Institut National de la Santé Et de la Recherche Médicale, France

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2027-01-07
Completion
2027-01-07
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736381 on ClinicalTrials.gov